---
title: Culture System for Isolating Circulating Tumor cells_2
nct_id: NCT04125667
overall_status: UNKNOWN
sponsor: National Taiwan University Hospital
study_type: OBSERVATIONAL
primary_condition: Early Diagnosis
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04125667.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04125667"
ct_last_update_post_date: 2019-10-14
last_seen_at: "2026-05-12T07:19:23.813Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Culture System for Isolating Circulating Tumor cells_2

**Official Title:** Culture System for Isolating Circulating Tumor Cells

**NCT ID:** [NCT04125667](https://clinicaltrials.gov/study/NCT04125667)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 45
- **Lead Sponsor:** National Taiwan University Hospital
- **Conditions:** Early Diagnosis, Diagnostic Techniques and Procedures
- **Start Date:** 2019-10-31
- **Completion Date:** 2020-08-31
- **CT.gov Last Update:** 2019-10-14

## Brief Summary

This culture system utilizes the special affinity difference of biomedical material coating for different cells to achieve the effect of isolating tumor cells from the blood sample. The coating of the system has the characteristic that to make the WBCs adhesion, but the cancer cells in the blood sample suspend in the culture medium, which achieves the effect of separating cancer cells from the blood. The supernatant with the cancer cells can further be isolated from the cultural system for related analysis and detection to achieve early diagnosis and screening.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with lung cancer are between the ages of 20 and 70
* Willing to sign the consent form under the informed consent

Exclusion Criteria:

* Vulnerable Subjects included minors, prisoners, aborigines, pregnant women, people with mental disorders, students, and subordinates, etc.
```

## Primary Outcomes

- **The Number of Circulating Cancer Cells from The Blood Sample** _(time frame: about 1 week)_ — The number of circulating cancer cells from the blood sample will be investigated. To distinguish cancer cells from blood cells for the system, the lung cancer cells were immunofluorescence stained for Cytokeratin, white blood cells were stained for CD45 and nuclei were counterstained with DAPI.

## Secondary Outcomes

- **Cancer Cell Isolation Efficiency of The Isolation System** _(time frame: about 1 week)_

## Locations (1)

- National Taiwan University Hospital, Taipei, Taiwan — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.national taiwan university hospital|taipei||taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04125667.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04125667*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*